6.46106133701533E-05 0.00114145416953831 0.000387663680220552 -0.00103376981392135 0.00157219159200555 -0.000366126809097086 0.00128144383184017 -0.00272441419710542
Sign Up Today X
Thanks for submitting the form.
Stockreport

Did Vertex's (VRTX) Earnings Beat and Advancing Pipeline Just Shift Its Investment Narrative? [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Beyond its cystic fibrosis franchise, the company's pipeline momentum, including candidates like povetacicept for kidney disease and launches in severe disorders, is becoming an increasingly important driver of investor attention. Next, we'll examine how this combination of an earnings beat and growing confidence in Vertex's pipeline shapes its broader investment narrative. Find 47 companies with promising cash flow potential yet trading below their fair value Vertex Pharmaceuticals Investment Narrative Recap To own Vertex, you need to believe its cystic fibrosis cash flows can support a broader portfolio in gene editing, pain and kidney disease, while managing high R&D and pricing pressures. The recent revenue beat and reaffirmed recurring revenue story support near term confidence in that thesis, but do not materially change the key risk that new CF competitors or curative approaches could eventually challenge its core franchise. The BMO Capital update, which reiterated a [Read more]
IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VRTX alerts
from News Quantified
VRTX
NEWS
VRTX
Earnings
VRTX
Analyst Actions
VRTX
SEC Filings
Stockreport

Did Vertex's (VRTX) Earnings Beat and Advancing Pipeline Just Shift Its Investment Narrative? [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated  (VRTX) 
More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Beyond its cystic fibrosis franchise, the company's pipeline momentum, including candidates like povetacicept for kidney disease and launches in severe disorders, is becoming an increasingly important driver of investor attention. Next, we'll examine how this combination of an earnings beat and growing confidence in Vertex's pipeline shapes its broader investment narrative. Find 47 companies with promising cash flow potential yet trading below their fair value Vertex Pharmaceuticals Investment Narrative Recap To own Vertex, you need to believe its cystic fibrosis cash flows can support a broader portfolio in gene editing, pain and kidney disease, while managing high R&D and pricing pressures. The recent revenue beat and reaffirmed recurring revenue story support near term confidence in that thesis, but do not materially change the key risk that new CF competitors or curative approaches could eventually challenge its core franchise. The BMO Capital update, which reiterated a [Read more]
IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS